What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2017?
5 analysts have issued twelve-month price objectives for Progenics Pharmaceuticals' stock. Their predictions range from $11.00 to $14.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $11.60 in the next twelve months.
When will Progenics Pharmaceuticals announce their earnings?
Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 9th 2017.
What are analysts saying about Progenics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
- Needham & Company LLC analysts commented, "We recently chose PGNX as our Top Pick for 2017 and are now going one step further and upgrading it to Strong Buy. We continue to expect significant appreciation in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. Our increased $14 price target reflects the introduction of estimates for the 1404 imaging agent, which recently passed an interim analysis in its pivotal trial." (2/6/2017)
According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (1/10/2017)
Who owns Progenics Pharmaceuticals stock?
Progenics Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Federated Investors Inc. PA (17.54%), Broadfin Capital LLC (12.78%), FMR LLC (5.11%), Pinnacle Associates Ltd. (3.80%), State Street Corp (2.94%) and Royce & Associates LP (2.08%). Company insiders that own Progenics Pharmaceuticals stock include Healthcare Master Fun Broadfin and Robert J Israel.
Who sold Progenics Pharmaceuticals stock? Who is selling Progenics Pharmaceuticals stock?
Progenics Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Federated Investors Inc. PA, Royce & Associates LP, Dimensional Fund Advisors LP, Pinnacle Associates Ltd., Cadence Capital Management LLC, Turner Investments LLC and Ellington Management Group LLC.
Who bought Progenics Pharmaceuticals stock? Who is buying Progenics Pharmaceuticals stock?
Progenics Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management, FMR LLC, Bogle Investment Management L P DE, Pacad Investment Ltd., State Board of Administration of Florida Retirement System, GSA Capital Partners LLP and Dynamic Technology Lab Private Ltd.
How do I buy Progenics Pharmaceuticals stock?
Shares of Progenics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Progenics Pharmaceuticals stock cost?
One share of Progenics Pharmaceuticals stock can currently be purchased for approximately $10.36.